E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
acute myocardial infarction with ST segment elevation |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 8.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10064345 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To investigatre the effect of pre-hospital treatment with a high bolus dosage of Tirofiban (in addition to Aspirin, Heparin and 600 mg Clopidogrel) on the extent of residual ST segment deviation 1 hour after Primary Coronary Angioplasty for acute myocardial infarction, compared to no pre-treatment (besides Aspirin, Heparin and 600 mg Clopidogrel). |
|
E.2.2 | Secondary objectives of the trial |
1. To investigate the effect of pre-hospital treatment with a high bolus dosage of Tirofiban on the incidence of the combined occurrence of death, recurrent MI, urgent TVR or thrombotic bailout at 30 days follow-up, compared to no pre-treatment. 2. To investigate the effect of pre-hospital treatment with a high bolus dosage of Tirofiban on the incidence of major bleeding compared to no pre-treatment. 3. To investigate the effect of pre-hospital treatment with a high bolus dosage of Tirofiban on the incidence of TIMI 3 flow of the infarct related vessel (IRV) at initial angiography, compared to no pre-treatment. |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Title: OnTime-2 MRI Substudy, Final Version date 14-Sep-2006
MRI has been shown to allow a comprehensive and accurate evaluation of cardiac function, volumes, wall motion with wall thickening, and myocardial viability. The aim of this substudy is to evaluate whether there is a difference between the group with upfront pre-treatment with a high bolus dosage of Tirofiban compared to no pre-treatment (besides Aspirin, Heparin and 600 mg of Clopidogrel).
The Magnetic resonance imaging protocol ( at baseline and on 4 months follow-up) covers: volumetric analysis of left ventricle (size, volumes, and ejection fraction), assessment of wall motion and thickening following the AHA 17-segment model, assessment of myocardial viability (measurement of infarct size, microvascular obstruction zones, and infarct transmurality)
|
|
E.3 | Principal inclusion criteria |
1. Males or females >= 21 years of age <= 85 years with symptoms of acute myocardial infarction of more than 30 minutes but less than 24 hours. 2. ST segment elevation of > 1 mV in 2 adjacent ECG leads, with cumulative ST segment deviation of 6 mm or more. 3. Patients should only be included if there is a reasonable expectation that PCI will be conducted within 2 hours. |
|
E.4 | Principal exclusion criteria |
1. Patients who are unable to give informed consent or have life expectanc of < 1 year. 2. Patient with left bundle branch block. 3. Patients who have received thrombolytic therapy within 24 hours or warfarin in last 7 days or another GpIIb/IIIa within last 30 days. 4. Patients who have known severe renal dysfunction or receiving dialysis or previously undertaken renal transplantation. 5. Patients with confirmed or persistent severe hypertension at randomization. 6. Patients with a contraindication to anticoagulation ar at increased bleeding risk. 7.Patients who have received another investigational drug or device or participated in any clinical trial within 4 weeks prior to randomization 8. Patients in cardiogenic shock or needing IABP. 9. Patients with known Hb < 11 gm/gl or HCT < 33%. 10. Hypersensitivity to any component of Tirofiban or Aspirin or Heparin or Clopidogrel. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
To investigate the effect of pre-treatment with 25 microgram/kg bolus and maintenance infusion Tirofiban on the amount of residual cumulative ST deviation 1 hour after Primary Coronary Angioplasty for acute mypcardial infarction, compared to no pre-treatment. The absolute level of the ST segment deviation will be measured by digital caliper to the nearest 0.01 mv 20ms after the end of the QRS interval using the TP segment as isoclectic baseline. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 20 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 28 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 30 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 30 |